Figure 5.

Lower glycocalicin circulating levels in platelets from patients with faster COX-1 recovery depend on higher GPIbcx expression, lower phosphatidylserine expression and lower ADAM17 activation, and enhance thrombopoietin mRNA transcription in liver cells. GPIbα protein levels in platelets of healthy subjects (HS) (n=4) vs. first (n=4) vs. third (n=4) tertile in all patients (A). ADAM17 levels in platelets of HS (n=3) vs. first (n=4) vs. third serum thromboxane B₂ (sTXB₂) slope tertile (n=4) in all patients (B). Phosphatidylserine (PS)-positive platelets (%CD41a+/AnV+) in the first (n=34) vs. third tertile (n=20) in all patients (C). PS-positive platelets (%CD41a+/AnV+) (D) and active-ADAM17 cleaved form (E) in 4 healthy subjects treated with low-dose aspirin, at 10 and 24 hours post aspirin. Treatment of HepG2 cells (n=4) with an increasing concentrations of human recombinant glycocalicin (rGC, 0.5, 1 and 2 µg/mL) is associated, after 1 hour of incubation, with a significant dose-dependent reduction in thrombopoietin (TPO) mRNA (F). Significance was calculated by Mann-Whitney U test or by Student’s t test.